Corma-Gomez, Anais , Fernandez-Fuertes, Marta , Vinuela, Laura , Dominguez, Carmen , Santos, Marta , Fuentes-Lopez, Ana , Rojas, Almudena , Fernandez-Perez, Nieves , Martin-Carmona, Jessica , Serrano-Conde, Esther , Real, Luis M. , Mendoza, Joaquin , Macias, Juan , Pineda, Juan A. , Garcia, Federico
No
J. Med. Virol.
Article
Científica
1
1
6.8
1.56
01/03/2023
9,60341E+11
The aim of this study was to assess the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines among people living with HIV (PLWH) with severe immunosuppression, after a booster dose. The design was a case-control study nested in a prospective cohort of PLWH. All patients with CD4 cell count <200 cells/mm(3) who had received additional dose of messenger RNA (mRNA) COVID-19 vaccine, after a standard immunization scheme were included. Control group: patients age- and sex-matched, with CD4 >= 200 cells/mm(3), in the ratio of 2:1. Antibody response to a booster dose (anti-S levels 33.8 >= BAU/mL) and neutralizing activity against SARS-CoV-2 B.1, B.1.617.2, and Omicron BA.1, BA.2, and BA.5 strains were assessed after the booster shot. Fifty-four PLWH were included, 18 with CD4 counts < 200 cells/mm(3). Fifty-one (94%) showed response to a booster dose. Response was less frequent in PLWH with CD4 < 200 cells/mm(3) than in those with CD4 counts >= 200 cells/mm(3) (15 [83%] vs. 36 [100%], p = 0.033). In the multivariate analysis, CD4 counts >= 200 cells/mm(3) [incidence rate ratio (IRR) = 18.1 (95% confidence interval [CI]: 16.8-19.5), p < 0.001] was associated with a higher probability of showing antibody response. Neutralization activity against SARS-CoV-2 B.1, B.1.617, BA.1, and BA.2 strains was significantly inferior among individuals with CD4 counts < 200 cells/mm(3). In conclusion, among PLWH with CD4 counts < 200 cells/mm(3), the immune response elicited by mRNA additional vaccine dose is reduced.
CD4 T-cell counts; immune response; people living with HIV; SARS-CoV-2; vaccine